Build status - In Progress

A Randomized Double-blind Multicenter Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants with Treatment-resistant Depression

Recruiting
99 years or below
All
Phase 3
8 participants needed
1 Location

Brief description of study

this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 mg and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with TRD, as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to end of the 4-week double-blind treatment phase (Day 28).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: depression, treatment resistant depression, TRD
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 844402

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center